Menu
GeneBe

ACSL4

acyl-CoA synthetase long chain family member 4, the group of Acyl-CoA synthetase family

Basic information

Region (hg38): X:109624243-109733403

Previous symbols: [ "FACL4", "MRX63", "MRX68" ]

Links

ENSG00000068366NCBI:2182OMIM:300157HGNC:3571Uniprot:O60488AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • non-syndromic X-linked intellectual disability (Moderate), mode of inheritance: XL
  • intellectual disability, X-linked 63 (Strong), mode of inheritance: XLR
  • non-syndromic X-linked intellectual disability (Supportive), mode of inheritance: XL
  • intellectual disability, X-linked 63 (Strong), mode of inheritance: XL
  • intellectual disability, X-linked 63 (Strong), mode of inheritance: XL
  • non-syndromic X-linked intellectual disability (Definitive), mode of inheritance: XL

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Intellectual developmental disorder, X-linked 63XLGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingNeurologic10854107; 11889465; 12525535

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the ACSL4 gene.

  • not provided (76 variants)
  • Inborn genetic diseases (24 variants)
  • Intellectual disability, X-linked 63 (20 variants)
  • not specified (19 variants)
  • Intellectual disability (3 variants)
  • ACSL4-related condition (2 variants)
  • Non-syndromic X-linked intellectual disability (2 variants)
  • Autism spectrum disorder (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the ACSL4 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
11
clinvar
3
clinvar
16
missense
1
clinvar
56
clinvar
7
clinvar
1
clinvar
65
nonsense
1
clinvar
1
start loss
0
frameshift
2
clinvar
2
clinvar
1
clinvar
5
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
1
clinvar
1
splice region
5
1
1
7
non coding
3
clinvar
3
clinvar
7
clinvar
13
Total 2 3 65 21 11

Variants in ACSL4

This is a list of pathogenic ClinVar variants found in the ACSL4 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
X-109624334-G-A Likely benign (Feb 28, 2019)1318086
X-109624598-C-T not specified Likely benign (Mar 03, 2022)1738980
X-109624611-T-C not specified Uncertain significance (Mar 29, 2022)2279985
X-109624618-G-C not specified Uncertain significance (Jul 15, 2023)2626405
X-109624620-G-T not specified Uncertain significance (Aug 28, 2023)2598706
X-109624624-G-A Brugada syndrome Uncertain significance (Apr 28, 2021)1480735
X-109624625-C-G Brugada syndrome Likely benign (Jul 03, 2021)1593076
X-109624634-G-C Brugada syndrome Likely benign (Jan 08, 2023)1592094
X-109624647-C-T Brugada syndrome Uncertain significance (Sep 22, 2022)1913506
X-109624650-C-A Brugada syndrome Uncertain significance (Aug 28, 2021)1476645
X-109624663-G-A Brugada syndrome • KCNE5-related disorder Uncertain significance (Feb 21, 2024)2037852
X-109624670-C-T Brugada syndrome Likely benign (Mar 01, 2022)2038831
X-109624672-C-T Brugada syndrome Uncertain significance (Feb 02, 2022)1053085
X-109624675-C-A not specified Uncertain significance (Jan 18, 2023)2449947
X-109624675-C-T Brugada syndrome • not specified Conflicting classifications of pathogenicity (Jan 17, 2024)532062
X-109624682-G-A Brugada syndrome • not specified Likely benign (Sep 22, 2023)1966470
X-109624683-GC-TT Brugada syndrome Uncertain significance (Dec 01, 2021)1410843
X-109624685-G-T Brugada syndrome Uncertain significance (Mar 28, 2021)1492489
X-109624687-C-T Brugada syndrome • not specified Conflicting classifications of pathogenicity (Jan 22, 2024)463282
X-109624688-G-A Brugada syndrome • not specified Benign/Likely benign (Jan 17, 2024)1169942
X-109624691-G-A not specified Likely benign (Nov 20, 2022)2449946
X-109624691-G-C not specified Likely benign (May 11, 2023)2564613
X-109624692-G-T Brugada syndrome Uncertain significance (Jan 31, 2021)1358440
X-109624694-C-G Brugada syndrome • not specified Likely benign (Jul 05, 2023)2196559
X-109624696-G-A Brugada syndrome • not specified Likely benign (Jun 02, 2022)532154

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
ACSL4protein_codingprotein_codingENST00000340800 14109160
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.9810.0190125562061255680.0000239
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense2.591432610.5480.00001834685
Missense in Polyphen50119.640.417932100
Synonymous0.06939090.80.9910.000006421346
Loss of Function4.11325.30.1180.00000201448

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00007600.0000615
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.0001320.0000929
European (Non-Finnish)0.00003710.0000264
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses arachidonate and eicosapentaenoate as substrates.;
Disease
DISEASE: Mental retardation, X-linked 63 (MRX63) [MIM:300387]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non- syndromic X-linked mental retardation, while syndromic mental retardation presents with associated physical, neurological and/or psychiatric manifestations. {ECO:0000269|PubMed:11889465}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Alport syndrome with mental retardation, midface hypoplasia and elliptocytosis (ATS-MR) [MIM:300194]: A X-linked contiguous gene deletion syndrome characterized by glomerulonephritis, sensorineural hearing loss, mental retardation, midface hypoplasia and elliptocytosis. {ECO:0000269|PubMed:9480748}. Note=The gene represented in this entry may be involved in disease pathogenesis.;
Pathway
Adipocytokine signaling pathway - Homo sapiens (human);Peroxisome - Homo sapiens (human);Thermogenesis - Homo sapiens (human);Fatty acid degradation - Homo sapiens (human);Fatty acid biosynthesis - Homo sapiens (human);PPAR signaling pathway - Homo sapiens (human);Ferroptosis - Homo sapiens (human);Fatty Acid Beta Oxidation;Fatty Acid Biosynthesis;Mitochondrial LC-Fatty Acid Beta-Oxidation;PPAR signaling pathway;Liver steatosis AOP;stearate biosynthesis;Metabolism of lipids;Fatty acyl-CoA biosynthesis;fatty acid activation;Leukotriene metabolism;Omega-3 fatty acid metabolism;Metabolism;Fatty acid metabolism;γ-linolenate biosynthesis;Mono-unsaturated fatty acid beta-oxidation;Omega-6 fatty acid metabolism;Di-unsaturated fatty acid beta-oxidation;Phytanic acid peroxisomal oxidation;fatty acid β-oxidation (peroxisome);icosapentaenoate biosynthesis II (metazoa);fatty acid β-oxidation;Synthesis of very long-chain fatty acyl-CoAs (Consensus)

Recessive Scores

pRec
0.308

Intolerance Scores

loftool
rvis_EVS
-0.56
rvis_percentile_EVS
19.31

Haploinsufficiency Scores

pHI
0.917
hipred
Y
hipred_score
0.768
ghis
0.629

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
S
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.872

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Acsl4
Phenotype
normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; skeleton phenotype; limbs/digits/tail phenotype; hearing/vestibular/ear phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype;

Zebrafish Information Network

Gene name
acsl4a
Affected structure
whole organism
Phenotype tag
abnormal
Phenotype quality
wholly dorsalized

Gene ontology

Biological process
long-chain fatty acid metabolic process;lipid metabolic process;response to nutrient;fatty acid transport;triglyceride biosynthetic process;long-chain fatty-acyl-CoA biosynthetic process;embryonic process involved in female pregnancy;dendritic spine development;response to interleukin-15
Cellular component
cytoplasm;mitochondrial outer membrane;peroxisomal membrane;endoplasmic reticulum membrane;lipid droplet;membrane;integral component of membrane;neuronal cell body;mitochondria-associated endoplasmic reticulum membrane;extracellular exosome
Molecular function
long-chain fatty acid-CoA ligase activity;ATP binding;very long-chain fatty acid-CoA ligase activity;arachidonate-CoA ligase activity;decanoate-CoA ligase activity